Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor

The systematic development and clinical application of genetically modified T cells is an example of how academic scientists working primarily at nonprofit medical centers are generating a new class of therapeutics. In this context, gene therapy has been used to overcome one of the major barriers to T-cell therapy of cancer, namely tolerance to desired target tumor-associated antigens (TAAs). This was achieved by the introduction of a chimeric antigen receptor (CAR) to redirect T-cell specificity to a TAA expressed on the cell surface. The prototypical CAR uses a mouse monoclonal antibody (mAb) that docks with a designated TAA and this binding event is reproduced by the CAR to trigger desired T-cell activation and effector functions. Multiple early-phase clinical trials are now under way or have been completed to evaluate the safety and feasibility of adoptive transfer of CAR⁺ T cells (Table 1). These pilot studies have revealed challenges in achieving reproducible therapeutic successes which may be solved by (1) reprogramming the T cells themselves for improved replicative potential, effector function, and in vivo persistence, (2) manipulating the recipient to improve TAA expression and survival of infused T cells, and (3) adapting the gene therapy platform to deliver (1) CARs capable of initiating an antigen-dependent fully-competent activation signal, and (2) transgenes to improve safety, persistence, homing, and effector functions within the tumor microenvironment. Academic investigators who work to both develop and deliver investigational biologic agents such as CAR⁺ T cells are poised to further tighten the pace of discovery between the bench and the bedside to improve the therapeutic potential of genetically modified T cells with redirected specificity. This review builds upon recent articles that describe the immunobiology of CAR⁺ T cells (Table 2) and we highlight how the CAR technology has been adapted to meet the challenges of infusing genetically modified T cells in medically fragile patients with aggressive malignancies and what new directions the field will need to embrace to undertake multicenter trials to prove their therapeutic efficacy.

The generation of T bodies, or CARs, by Eshhar et al has been adapted by investigators as a tool to enable T cells, as well as other immune cells, to overcome mechanisms (eg, loss of human leukocyte antigen [HLA]¹ ) by which tumors escape from immune surveillance of the patient's endogenous (unmanipulated) T-cell repertoire.^2,3  The specificity of a CAR is achieved by its exodomain which is typically derived from the antigen binding of a mAb linking the V_H and V_L domains to construct a single-chain fragment variable (scFv) region. The exodomains of CARs have also been fashioned from ligands or peptides (eg, cytokines) to redirect specificity to receptors (eg, cytokine receptors), such as the IL-13Rα2–specific “zetakine.”⁴  The exodomain is completed by the inclusion of a flexible (hinge) sequence, such as from CD8α or immunoglobulin sequence^5,6  and via a transmembrane sequence, the exodomain is fused to 1 or more endodomain(s) which may include cytoplasmic domains from CD3-ϵ, CD3-γ, or CD3-ζ from the T-cell receptor (TCR) complex or high-affinity receptor FcϵRI.^7-9  When CARs are expressed on the cell surface of genetically modified T cells, they redirect specificity to TAA (including TAA on tumor progenitor cells¹⁰ ) independent of major histocompatibility complex (MHC). This direct binding of CAR to antigen ideally provides the genetically modified T cell with a fully-competent activation signal, minimally defined as CAR-dependent killing, proliferation, and cytokine production. Given that T cells targeting tumor through an endogenous αβTCR (and even introduced TCR chains³⁴ ) exhibit such a fully-competent activation signal, investigators have iteratively designed and tested CARs, for example, with 1 or more activation motifs, to try and recapitulate the signaling event mediated by αβTCR chains. These changes to the CAR are enabled by the modular structure of a prototypical CAR and this has resulted in first-, second-, and third-generation CARs designed with 1, 2, or 3 signaling endodomains (Figure 1) including a variety of signaling motifs, such as chimeric CD28, CD134, CD137, Lck, ICOS, and DAP10.^6,35-37  A listing of such CARs is provided by Berry et al²⁶  and Sadelain et al.²⁷  While the optimal CAR design remains to be determined, at present it is believed that the first-generation technology, in which a CAR signals solely through immunoreceptor tyrosine-based activation motif (ITAM) domains on CD3-ζ, is insufficient to sustain in vivo persistence of T cells.³⁸  This is supported by early clinical data which demonstrate that CD19-specific,³⁹  CD20-specific,⁴⁰  GD₂-specific (not Epstein-Barr virus [EBV] bispecific),⁴¹  and L1-CAM (cell adhesion molecule)–specific⁴²  T cells had apparently short-lived persistence in peripheral blood. The decision regarding which second- or even third-generation CAR design to use in clinical trials is predicated on the ability of a CAR to activate T cells for desired T-cell effector function, which at a minimum includes CAR-dependent killing. However, it is possible that next-generation CARs can be engineered to provide a supraphysiologic activation signal which may be detrimental to continued T-cell survival and perhaps even the well-being of the recipient.⁴³ 

The inclusion of 1 or more T-cell costimulatory molecules within the CAR endodomain is in response to the appreciation that genetically modified and ex vivo–propagated T cells may have down-regulated expression of desired endogenous costimulatory molecules (eg, CD28) or that the ligands for these receptors may be missing on tumor targets (eg, absence of CD80/CD86 on blasts from B-lineage acute lymphoblastic leukemia). By way of example, chimeric CD28 and CD3-ζ,^38,44  CD137 and CD3-ζ,^23,36  or CD134 and CD3-ζ,^45,46  have been incorporated into the design of second-generation CARs with the result that these CARs with multiple chimeric signaling motifs exhibited effector function stemming from a both a primary signal (eg, killing) and costimulatory signal (eg, IL-2 production) after an extracellular recognition event.^47,48  Animal studies have demonstrated that T cells expressing a second-generation CD19-specific^36,38  and carcinoembryonic antigen-specific CAR⁴⁹  exhibited an improved antitumor effect compared with T cells bearing a first-generation CAR. In addition to altering the endodomains, investigators have also made changes to the scFv to improve affinity based on selecting high-affinity binding variants from phage arrays.^50,51  The approach to developing CAR⁺ T cells with a calibrated increase in functional affinity may be necessary to enable genetically modified T cells to target tumors with low levels of antigen expression or perhaps to target a cell-surface molecule in the presence of soluble antigen.^52,53  Because a CAR typically contains a murine scFv sequence which may be subject to immune recognition leading to deletion of infused T cells, investigators have developed humanized scFv regions to target carcinoembryonic antigen (CEA)^54,55  and ERBB2 (a member of epidermal growth factor receptor family).⁶  However, a benefit for using human or humanized scFv regions is yet to be established in the clinical setting.

The ability to genetically modify T cells to redirect specificity provides investigators with a platform to express other transgenes such as for noninvasive imaging. Such temporal-spatial imaging is desired as a surrogate marker for a CAR-mediated antitumor effect and to serially determine number and localization of infused T cells. One imaging transgene coexpressed with CAR is thymidine kinase (TK) and associated mutants from herpes simplex virus-1 (HSV-1)⁵⁶  which can be used to enzymatically trap radioactive substrates within the cytoplasm to image the locoregional biodistribution of T cells using positron emission tomography.^57-59  The expression of TK also renders CAR⁺ T cells sensitive to conditional ablation using ganciclovir in a cell-cycle–dependent manner.^60-62 

Approaches to the genetic manipulation of T cells for the introduction of CAR transgene use either viral-mediated transduction, or nonviral gene transfer of DNA plasmids or in vitro–transcribed mRNA species. The advantage of retrovirus^63-65  or lentivirus^23,36,66,67  to modify populations of T cells lies in the efficiency of gene transfer, which shortens the time for culturing T cells to reach clinically-significant numbers (Figure 2). Gamma retroviruses, the most common vector system used to genetically modify clinical grade T cells (Figure 3), have introduced CAR into T cells with a proven ability to exert a therapeutic effect.⁴¹  Self-inactivating lentiviral vectors (Figure 3) hold particular appeal as they apparently integrate into quiescent T cells.²⁸  These recombinant viruses often have a high cost to manufacture at clinical grade in specialized facilities skilled in current good manufacturing practice (cGMP) which may preclude investigators from undertaking clinical trials. As an alternative to transduction, we and others have adapted electroporation as an approach to the nonviral gene transfer of DNA^42,70,71  resulting in CAR⁺ T cells that have been attributed to have an antitumor effect in a clinical trial.⁴⁰  Previously, the electrotransfer and integration of naked plasmid DNA into T cells was considered inefficient because it depended on illegitimate recombination for stable genomic insertion of nonviral sequences. As a result, lengthy in vitro culturing times were required to select for T cells bearing stable integrants^72,73  during which period the T cell became differentiated, and perhaps terminally differentiated, into effector cells which may have entered into replicative senescence. This time in tissue culture can now be considerably shortened by using transposon/transposase systems such as Sleeping Beauty (SB)^70,74,75  and piggyback^76,77  to stably introduce CAR from DNA plasmids (Figure 3).^71,76,78-84  We have shown that the SB system can be used to introduce CAR and other transgenes into human T cells with an approximately 60-fold improved integration efficiency compared with electrotransfer of DNA transposon plasmid without transposase⁷⁴  and this provided the impetus to adapt the SB system for use in clinical trials.⁸⁵  After electroporation, T-cell numbers from peripheral and umbilical cord blood can be rapidly increased in a CAR-dependent manner by recursive culture on γ-irradiated artificial antigen-presenting cells (aAPC) achieving clinically sufficient numbers of cells for infusion within 3 to 4 weeks after electroporation (Figure 2). Given that T cells transduced with γ-retrovirus are typically cultured with OKT3 and IL-2 for approximately 3 weeks before infusion, the use of the SB system with aAPC does not appear to greatly lengthen the ex vivo culturing process.

T cells and polarized T-cell subsets, such as T_H1 and T_H17 cells, may be genetically modified to be specific for a catalog of cell-surface TAAs as described in recent reviews (Table 2). To enable these CAR⁺ T cells to achieve their full therapeutic potential in clinical trials, there are 3 major challenges to be overcome.

The adoptively transferred CAR⁺ T cells must survive and perhaps also numerically expand to achieve a robust antitumor effect. One approach to improving persistence is to alter the host environment into which the T cells are infused. For example, rendering the recipient lymphopenic, or even aplastic by chemotherapy and/or radiation therapy, improves the persistence of adoptively transferred T cells (and natural killer [NK] cells).^86-90  Presumably, the infused T cells proliferate in the lymphopenic recipient through homeostatic mechanisms mediated by the removal of regulatory/suppressor cells and the ready availability of previously scarce homeostatic cytokines. This approach likely improves in vivo persistence and thus efficacy of CAR⁺ T cells as a published trial and animal studies have hinted.⁴⁰  However, combining chemotherapy and T-cell therapy might increase toxicity and compromise the interpretation of an antitumor effect for it may be difficult to definitively attribute efficacy to the infused CAR⁺ T cells in trials enrolling small numbers of patients who received concomitant chemotherapy. Trials infusing T cells expressing a first-generation CAR design (signaling solely through chimeric CD3-ζ endodomain) revealed that these T cells appear to have limited long-term persistence and one way of circumventing this limitation is to engineer CAR endodomains to deliver an activation signal for sustained proliferation. This has been achieved by the design of second-generation CARs that signal through 2 signaling domains and these are now in multiple clinical trials. Third-generation CARs are now being evaluated in humans in a few trials (Table 1) which are composed of 3 chimeric signaling moieties.^6,35  Rather than modifying the CAR design to sustain proliferation, investigators have used signaling molecules alongside CARs to achieve improved persistence. For example, constitutively expressed recombinant CD80 and CD137L alongside the CAR demonstrated coordinated signaling between these 2 introduced receptors with endogenous ligands CD28 and CD137 within the immunologic synapse on or between T cells, which could improve antitumor effects.⁹¹  CAR has been introduced into T cells expressing endogenous αβTCR that recognize allo-⁹²  or viral antigens.^41,93-95  Triggering such TCRs in vivo can be used to numerically expand T cells to achieve an improved antitumor effect delivered by the CAR as was recently demonstrated by infusing bispecific T cells which recognized EBV-specific antigens via the endogenous αβTCR and GD₂ on neuroblastoma cells by the introduced CAR.⁴¹  Because T cells may require exogenous cytokines to sustain in vivo persistence,⁹⁶  investigators have enforced expression of cytokines that signal through the common γ cytokine receptor chain. Animal experiments⁹⁷  as well as clinical experience^98,99  have shown that long-lived T cells are associated with expression of the IL-7Rα chain (CD127), but genetically modified and cultured T cells tend to down-regulate this receptor. Therefore, to enhance the ability of T cells to respond to IL-7, made available after inducing lymphopenia,^100-102  investigators have enforced the expression of IL-7Rα to demonstrate improved survival of EBV-specific T cells in an animal model¹⁰³  or introduced a novel membrane-bound variant of IL-7 that when expressed on the cell surface improved persistence of CAR⁺ T cells.¹⁰⁴  Furthermore, overexpression of receptors for IL-2¹⁰⁵  and IL-15¹⁰⁶  as well as enforced expression of the cytokines themselves¹⁰⁷  have improved persistence of T cells.^108-110  However, when this approach was tested in a clinical trial infusing tumor-infiltrating lymphocytes (TIL) genetically modified to constitutively secrete IL-2, the persistence of the adoptively transferred T cells was not improved compared with genetically unmodified TIL.¹¹¹  As constitutive expression of cytokines and/or cytokine receptors is tested in early clinical trials, investigators will need to consider coexpressing transgenes for conditional ablation of these genetically modified T cells to guard against aberrant proliferation as unopposed cytokine signaling may lead to aberrant T-cell growth.^109,112  The type of T cell into which the CAR is introduced may also impact persistence after adoptive immunotherapy. This has been demonstrated in the monkey by infusing autologous preselected central memory T cells which despite ex vivo numeric expansion retained superior in vivo persistence compared with adoptive transfer of differentiated effector T cells.¹¹³  These observations have been expanded upon by Hinrichs et al who showed that an infusion of naive murine T cells was associated with improved T-cell persistence.¹¹⁴  These animal observations are likely to influence the design of trials infusing genetically modified T cells as investigators seek to introduce CARs into T cells that preserve the functional capacity of central memory or naive T cells.

To act on and within the tumor, genetically modified T cells must home to the site(s) of malignancy. Migration may be compromised by the loss of desired chemokine receptors during genetic modification and passage ex vivo, or may result from the selection of T cells that are inherently unable to localize to certain tissues. Panels of tissue-specific homing receptors which are typically composed of integrins, chemokines, and chemokine receptors are associated with T-cell migration to anatomic sites of malignancy, and flow cytometry can therefore be used to describe the potential migration patterns of T cells before infusion.^115,116  It is unclear whether T cells capable of expressing a desired matrix of endogenous homing receptors can be genetically modified to express CAR. Therefore, investigators are manipulating the homing potential of T cells through the enforced expression of chemokine receptors such as CCR4.^117,118 

Once infused T cells persist and home, they must be able to execute and recycle their CAR-dependent effector function, which requires an ability to overcome the adverse regulatory effects within the tumor microenvironment. For example, investigators have introduced a dominant-negative receptor for TGFβ to enable genetically modified T cells can resist the suppressive effects of this pleiotropic cytokine.¹¹⁹  Recognizing that the tumor microenvironment contains regulatory T cells (T_regs), the CAR signaling motif has been adapted to resist the suppressive effects of these cells by the expression of chimeric CD28.¹²⁰  The ability to engineer CAR⁺ T cells to successfully function within tumor deposits remains relatively underexplored as most clinical trials to date have used CAR⁺ T cells with specificity for hematopoietic malignancies. However, trials have been published and are under way which seek to treat solid tumors^41,42,121  (Table 1) and systematic approaches to enabling infused T cells to effectively operate within a tumor microenvironment will be needed to reliably eliminate large tumor masses.

The ex vivo gene transfer and propagation (Figure 2) of T cells provides an opportunity to further manipulate T cells before infusion. The in vitro propagation of T cells provides investigators with an opportunity to numerically expand T cells from scant starting numbers, such as when T cells are genetically modified from umbilical cord blood with the intent to augment the graft-versus-tumor-effect after allogeneic hematopoietic stem cell transplantation (HSCT).⁶¹  However, the in vitro culturing process can also be adapted to modify T cells for desired effector function by the selective addition of a subset of soluble cytokines, for example, that bind via common γ chain receptor to the culture media during ex vivo culture.^122,123  In addition, to help maintain a desired T-cell phenotype after gene transfer, investigators have provided costimulatory signals by the addition of CD28-specific mAb in addition to OKT3, often using beads conjugated to these mAbs. As an alternative, we and others have used immortalized cells in tissue culture, such as 3T3^124,125  and K562^74,126-128  which can be genetically modified to express desired T-cell costimulatory molecules and function when irradiated as aAPC.

Populations of hematopoietic cells other than T cells expressing αβTCR, such as NK cells, cytokine-induced killer (CIK) cells, monocytes, and neutrophils have been genetically modified to express CARs.^27,28  Given the inherent lytic potential of NK cells, redirection of their specificity via a CAR is appealing.^129-133  CAR signaling endodomain(s) can be specifically adapted or chosen to enhance NK-cell signaling versus those that activate T cells.¹³⁴  One drawback to adoptive transfer of NK cells has been their limited survival in vivo after transfer. However, ex vivo NK-cell culturing using aAPC adapted from K562 may change this perception.^135,136  Furthermore, the use of NK cells as a cellular platform for introducing CARs may be attractive after allogeneic HSCT as donor-derived NK cells do not appear to significantly contribute to graft-versus-host-disease (GVHD).^137,138  T cells expressing γδTCR are another lymphocyte population with endogenous killing ability that has been modified to express CAR, and these cells can be selectively proliferated using an aminobiphosphonate (Zoledronate),¹³⁹  raising the possibility that a Food and Drug Administration (FDA)–approved pharmacologic agent can be used to selectively propagate these infused CAR⁺ T cells in vivo. Instead of genetically modifying mature lymphocytes to express CAR, investigators have introduced CAR into developing thymocytes¹⁴⁰  and immunoreceptors into hematopoietic stem cells (HSC)^141-143  to avoid negative selection and improve immune-mediated surveillance. The approach of genetically modifying lymphoid precursors has also been adapted by Zakrzewski et al to make “universal T cells” in which CAR⁺ HSC can be adoptively transferred across MHC barriers.¹⁴⁴  It is only a matter of time until embryonic stem cells and induced pluripotent stem cells are genetically modified to express CAR and differentiated into T cells with redirected and desired specificity. The question remains, however, whether these other populations of cells have a therapeutic advantage over genetic modification and infusion of αβ⁺ T cells that are genetically modified to express CAR.

There are 4 levels of concern associated with the infusion of genetically modified T cells. The first is whether the introduced genetic material can lead to genotoxicity. This remains a theoretical concern for genetically modified T cells, in contrast to HSC.¹⁴⁵  The stable expression of CAR requires the introduction of a promoter and the transgene cDNA which raises the possibility of insertional mutagenesis. However, to date, there have been no genotoxic events associated with serious adverse events attributed to genetically modified T cells that have been transduced by recombinant virus or electroporated to introduce DNA plasmid.¹⁴⁶  The risk for insertional mutagenesis can be alleviated by the electrotransfer of in vitro transcribed mRNA coding for a CAR. The introduction of mRNA into activated T cells is efficient and as technologies improve to synchronously electroporate large numbers of cells, it may be possible to overcome the expected loss of CAR expression from transient transfection by repeatedly electroporating and administering CAR⁺ T cells and NK cells.^133,147  Regarding the risks of transposition, a review has been published discussing the risks and benefits of the SB system for clinical application which addresses the low potential for genotoxicity.¹⁴⁸  For additional reviews on insertional mutagenesis in genetically modified T cells, please refer to Table 2. A second area of concern is whether the CAR can exhibits deleterious effects by damaging normal structures. This remains a concern for all CARs infused in clinical trials as the targeted TAA may also be expressed on the cell surface of normal cells. A clinical trial demonstrated that a low level of carbonic anhydrase expression on normal liver cells led to hepatotoxicity when carbonic-anhydrase-IX (CAIX)–specific T cells were infused to treat metastatic renal cell carcinoma.¹⁴⁹  Furthermore, evidence appears to indicate that low-level expression of ERBB2 on normal lung cells may be associated with the sudden death of a patient at the National Cancer Institute (NCI) who received autologous HER2-specific T cells expressing a third-generation CAR along with IL2.⁴³  The risks versus benefits must be calculated for a given patient and a given CAR on case-by-case basis. For example, at present it remains an acceptable risk to infuse CD19-specific T cells, which will not distinguish between CD19 expressed on malignant B cells versus normal B cells, in patients with aggressive B-lineage malignancies, as the risk of loss of normal B-cell function is offset by the potential benefit from an antitumor effect. The third area of concern is the type of T cell being infused. For example, do the introduced transgenes render T cells capable of autonomous proliferation independent of binding TAA? Or, in the allogeneic setting, do the donor-derived T cells target major or minor histocompatibility antigens that can lead to GVHD? The risk of alloreactivity in the context of adoptive transfer of donor-derived CAR-modified T cells may be reduced using ex vivo educated virus-specific T cells which simultaneously provide antiviral protection against opportunistic viruses such as cytomegalovirus, adenovirus, and EBV, through their native αβTCRs, and antileukemia specificity through their transgenic CAR, thereby minimizing the risk of GVHD.¹⁵⁰  The fourth risk is the associated therapy that the patient receives along with the CAR⁺ T cells. For example, the use of lymphodepleting chemotherapy, especially in patients with large amounts of disease and/or poor performance scores (often the case for patients enrolled in phase 1 trials) can lead to attendant toxicities. Recently, Brentjens et al shared their experience infusing autologous CD19-specific T cells expressing a second-generation CAR in a heavily pretreated patient with advanced-stage chronic lymphocytic leukemia (CLL) who apparently died from a sepsis-like syndrome associated with acute renal failure after cyclophosphamide to achieve lymphodepletion.¹⁵¹  In response to these serious adverse events, the Office of Biotechnology Activities (OBA) at the National Institutes of Health (NIH) met on June 15, 2010 (http://oba.od.nih.gov/rdna_rac/rac_meetings.html) to discuss how to improve safety without compromising the potential efficacy of CAR⁺ T cells. The risks of adverse events caused by adoptive transfer of CAR⁺ T cells can also be mitigated by coexpression of a conditional suicide gene, such as HSV-1 TK expressed in haploidentical T cells after allogeneic HSCT to mitigate GVHD.¹⁵²  A drawback, however, is that the introduced transgene (such as viral-derived TK) is potentially immunogenic which can, on occasion, lead to unwanted immune-mediated destruction, and thus loss of persistence of genetically modified T cells.^153-155  However, the degree of immunosuppression induced in the recipient and level of transgene expression likely determine the immunogenicity of the genetically modified cell.¹⁵⁶  There are potentially less-immunogenic approaches to rendering T cells sensitive to conditional ablation such as expressing a mutant of human thymidylate kinase¹⁵⁷  as well as activating Fas (the tumor necrosis factor receptor superfamily member 6) and inducible caspase 9 using a commercial dimerizing agent, which is currently in a clinical trial and has been successfully coexpressed with CAR without impairing its function.^158,159  Furthermore, CD20 has been introduced as a nonimmunogenic suicide mechanism as CD20⁺ T cells could be eliminated by rituximab.^160,161  Given the rapidity of the 2 deaths after an infusion of CAR⁺ T cells (and that 1 death was not attributed to the T cells) it is likely that conditional ablation via a suicide gene would not have altered the kinetics or severity of these serious adverse events. Approaches to decreasing the probability of toxicity include interpatient and intrapatient T-cell dose escalation schemes and splitting a given T-cell dose over 2 or more days.

The therapeutic potential of CAR⁺ T cells may benefit from the addition of other immune modulators and biologic agents. For example, Tregs cells that might suppress CAR-dependent effector function can be eliminated by lymphodepleting chemotherapy or mAb therapy. To improve persistence after adoptive transfer, virus-specific CAR⁺ T cells might be administered along with antigen-presenting cells, such as derived from autologous T cells (T-APC) genetically modified to present a viral antigen recognized by the endogenous αβ TCR to activate CAR⁺ T cells for proliferation.⁹⁵  Similarly, alloreactive CAR⁺ T cells might be stimulated with alloantigen in vivo to improve persistence and therapeutic effect.⁹²  CAR⁺ T cells may also benefit from concomitant mAb therapy¹⁶²  or immunocytokine help to deliver targeted help.¹⁶³  CAR⁺ T cells may also be given with other cells, such as invariant natural killer T cells (iNKT) to sculpt the tumor microenvironment to improve T-cell function.

The safety of the research participants in trials infusing CAR⁺ T cells is of paramount importance. To maintain the well-being of patients multiple institutional and federal administrative layers of checks and balances have been developed. Thus, the trial's principal investigator and team not only need to develop the infrastructure to support infusing genetically modified T cells, but are required to also obtain approvals from institutional review committees (institutional review board [IRB] and institutional biosafety committee [IBC]) as well as federal regulatory authorities (NIH-OBA and FDA). Furthermore, the cGMP process itself contains checks and balances, as the manufacturing personnel are separate from the quality control program which in turn is separate from the quality assurance team. These processes have emerged to prevent serious adverse events from faults in production of genetically modified T cells. Working within this governance structure takes specialized expertise and consumes time and funding as large documents and copious data are prepared and reviewed. If CAR⁺ T cells are to enter the mainstream of clinical practice, the regulatory processes will need to adapt so that multi-institution trials can be readily undertaken by academic centers.

The decision to infuse CAR⁺ T cells is undertaken at the programmatic level as well as at the bedside. Currently, such genetically modified T cells are primarily infused in patients with aggressive malignancies who have received multiple prior therapies, although some pilot trials are investigating infusing CAR⁺ T cells in patients with minimal residual disease and to prevent relapse in patients at high risk for disease progression. The risk of adoptively transferring genetically modified T cells is justified in these clinical scenarios as the underlying malignancy is considered resistant to conventional therapies. Thus, tolerance by regulators and administrative authorities is needed and appreciated regarding the expected toxicities that are likely to occur as new therapeutic approaches are evaluated in early phase trials enrolling medically fragile patients. Investigator-initiated trials must balance the risks versus benefits, but the pace of genetic therapies needs to accelerate.^164-166  One reason for the slow implementation of human studies using genetically modified T cells is that the design and activation of trials to infuse genetically modified T cells with redirected specificity has been expensive, but economies of scale and improvements in cGMP are rapidly driving down the associated costs. This is apparent from an application to the FDA for viral-specific T cells¹⁶⁷  to achieve orphan-drug status and their cost compares favorably with current antiviral medications. Indeed, if one considers genetically modified T cells as “drugs,” the costs associated with their generation and delivery compares favorably with other biologic therapies such as mAbs and HSCT.

Scientists working with CAR⁺ T cells benefit from being able to develop and infuse designer “drugs” that are personalized to the patient's needs and can be manufactured to clinical standards on academic campuses to treat orphan diseases free of the encumbrances associated with manufacturing concerns that generate drugs for profit. This ability to apply cell therapy makes the science of CAR⁺ T cells compelling not just for redirecting T-cell specificity, but establishes a framework for how nonprofit academic centers can organize their laboratories and resources to operate for all intents and purposes as biotechnology companies to generate a clinical product. Clinical translation of CAR⁺ T cells is promising given the clinical responses described in early phase trials (Table 1). However, trials powered for efficacy need to be undertaken at multiple centers, to establish the potential of CAR⁺ T cells to treat malignant disease and to impact clinical practice. The immunobiology of CAR⁺ T cells has reached a level of maturity where it is now the decision to undertake multicenter gene therapy trials and overcome the associated issues of indemnification and monitoring of an investigational new drug (IND) that will be a major challenge to solve over the next few years.

We thank Dr Malcolm Brenner at the Baylor College of Medicine and Dr Stephen Forman at the City of Hope for helpful discussions and review.

This work was supported by National Institutes of Health grants RO1CA124782 and R01CA120956.

National Institutes of Health

Contribution: B.J. and G.D. helped write the paper; and L.J.N.C. originated the concept and helped write the paper.

Conflict-of-interest disclosure: L.J.N.C. is the founder of InCellerate Inc. The remaining authors declare no competing financial interests.

Correspondence: Laurence J. N. Cooper, MD, PhD, Division of Pediatrics (Unit 907), M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; e-mail: ljncooper@mdanderson.org